Literature DB >> 7747449

Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys.

G Voss1, J Li, K Manson, M Wyand, J Sodroski, N L Letvin.   

Abstract

Because of the importance of the envelope glycoprotein (Env) in determining the pathogenicity of HIV-1 and the importance of the immune response to Env in controlling virus spread, attempts are being made to study HIV-1 Env-directed immunity in primate models. To date HIV-1 Env-specific effector T lymphocyte responses have not been demonstrated in virus-infected nonhuman primates. We have previously reported that cynomolgus monkeys can develop a persistent infection with a chimeric simian-human immunodeficiency virus (SHIV) composed of SIVmac239 carrying the HIV-1 env, tat, rev, and vpu genes. We now demonstrate that SHIV-infection of another macaque species, the rhesus monkey, generates persistent, HIV-1 Env-specific cytolytic T lymphocyte (CTL) responses. These CTL are CD8+ and major histocompatibility complex (MHC) class I-restricted. The induction of CTL was correlated neither to the virus load nor to the MHC class I haplotypes of the monkeys. The SHIV-infected rhesus monkey can, therefore, now be employed for studying effector T lymphocyte recognition of HIV-1 Env.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747449     DOI: 10.1006/viro.1995.1209

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

3.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.

Authors:  K A Reimann; J T Li; G Voss; C Lekutis; K Tenner-Racz; P Racz; W Lin; D C Montefiori; D E Lee-Parritz; Y Lu; R G Collman; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.

Authors:  G B Karlsson; M Halloran; J Li; I W Park; R Gomila; K A Reimann; M K Axthelm; S A Iliff; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Authors:  T M Fu; D C Freed; W L Trigona; L Guan; L Zhu; R Long; N V Persaud; K Manson; S Dubey; J W Shiver
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys.

Authors:  Y Yasutomi; H L Robinson; S Lu; F Mustafa; C Lekutis; J Arthos; J I Mullins; G Voss; K Manson; M Wyand; N L Letvin
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.